^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QTX3046

    i
    Other names: QTX3046, QTX 3046, QTX-3046
    Company:
    Quanta Therap
    Drug class:
    KRAS G12D inhibitor
    Related drugs:
    5ms
    QTX3046 in Patients With KRAS G12D Mutations (clinicaltrials.gov)
    P1, N=240, Recruiting, Quanta Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Erbitux (cetuximab) • QTX3046
    6ms
    QTX3046 in Patients With KRAS G12D Mutations (clinicaltrials.gov)
    P1, N=240, Not yet recruiting, Quanta Therapeutics
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Erbitux (cetuximab) • QTX3046
    over1year
    Discovery and characterization of QTX3046, a potent, selective, and orally bioavailable non-covalent KRASG12D inhibitor (AACR 2023)
    The systemic clearance in rats and dogs was high to moderate, respectively and despite low apparent permeability, demonstrated good oral bioavailability in each species. The current PK profile and preclinical proof-of-concept data support advancement of QTX3046 into IND enabling studies to support potential clinical investigation in KRASG12D-driven solid tumor indications.
    Late-breaking abstract
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12D • KRAS wild-type • RAS mutation
    |
    QTX3046